✦ LIBER ✦

9200 ORAL A Phase 3 Study Comparing Melphalan-Prednisone-Lenalidomide (MPR) With High-dose Melphalan and Autologous Transplantation (MEL200) in Newly Diagnosed Patients With Multiple Myeloma (MM)

✍ Scribed by Palumbo, A.; Cavallo, F.; Di Raimondo, F.; di Toritto, T. Caravita; Grammatico, S.; Corradini, P.; Omede, P.; Ben Yehuda, D.; Nagler, A.; Boccadoro, M.

Book ID: 122584112
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 40 KB
Volume: 47
Category: Article
ISSN: 0959-8049
DOI: 10.1016/S0959-8049(11)72465-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Risk factors for, and reversibility of,

Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib–melphalan–prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study

✍ Meletios A. Dimopoulos; Maria-Victoria Mateos; Paul G. Richardson; Rudolf Schlag 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 129 KB

Cyclophosphamide plus dexamethasone is a

Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma : Results of a randomized comparison with vincristine, doxorubicin, and dexamethasone

✍ Ulf-Henrik Mellqvist; Stig Lenhoff; Hans E. Johnsen; Martin Hjorth; Erik Holmber 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 153 KB 👁 2 views

## Abstract ## BACKGROUND Today, intensive therapy that includes high‐dose melphalan with autologous stem cell transplantation (ASCT) is considered standard therapy in younger patients with newly diagnosed myeloma. When the current trial was initiated, combined vincristine, doxorubicin, and dexame

Aprepitant for the control of delayed na

Aprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem cell transplants in patients with multiple myeloma: a phase II study

✍ Bechtel, Thomas; McBride, Ali; Crawford, Brooke; Bullington, Susan; Hofmeister, 📂 Article 📅 2014 🏛 Springer-Verlag 🌐 English ⚖ 248 KB

B152 First Analysis of HOVON-65/GMMG-HD4

B152 First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) vs. VAD as Induction Treatment Prior to High-dose Melphalan (HDM) in Patients with Newly Diagnosed Multiple Myeloma (MM)

✍ Sonneveld, P; Eljarari, L; Salwender, H; Zweegman, S; Vellenga, E; Van Der Holt, 📂 Article 📅 2009 🏛 CIG Media Group, LP. 🌐 English ⚖ 116 KB

A prospective, randomized study of cryot

A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation

✍ Maloney, D G; Press, O W; Bensinger, W; Lilleby, K; Garcia, P; Gooley, T; McDonn 📂 Article 📅 2006 🏛 Nature Publishing Group 🌐 English ⚖ 115 KB

184: Phase I Study of Bortezomib, (BTZ)

184: Phase I Study of Bortezomib, (BTZ) followed by High-Dose Melphalan, (HD Mel) and BTZ as Conditioning Regimen for Tandem Peripheral Blood Stem Cell Transplants (TanPSCT) in Patients with Primary Refractory Multiple Myeloma (MM) and Plasma Cell Leukemia (PCL)

✍ M. Alsina; T. Alekshun; C. McIsaac-Simonelli; M. Kharfan-Dabaja; W. Dalton; B. D 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 52 KB